Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Brain zaps to beat cravings: paris trial tests tDCS for smokers

NCT ID NCT04209153

Symptom relief Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study tests whether a non-invasive brain stimulation technique called tDCS can reduce cravings in people addicted to nicotine. One hundred daily smokers who are highly dependent will receive tDCS sessions. The goal is to see if this painless, mild electrical stimulation can lower the urge to smoke, offering a drug-free option to help people quit.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
transcranial direct current stimulation (tDCS)
What this could lead to
If it works, this could offer a non-drug way to help smokers control cravings and quit.
What could go wrong
This is an early-stage study with only 100 participants, so results may not apply widely. tDCS effects are mild and temporary, and the treatment may not lead to lasting smoking cessation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2021

Expected to finish

May 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

All tobacco smokers who will ask for consultation in our ward.

Ages

18 years and older

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Men and women over the age of 18 * Nicotine dependent subjects according to the Fagerström test (score ≥5) * Subjects consuming daily tobacco. * Subjects understanding and reading French and able to express themselves in this language. * Signed informed consent to participate indicating that the subject has understood the purpose and the procedures required by the study and agrees to participate in the study and to comply with the requirements and limitations of this study * Affiliation to the French social security scheme or beneficiary of such a scheme. * No other method to decrease or stop smoking at the same time as the study. Exclusion Criteria: * Guardianship * Pregnant or lactating woman * Patient under AME * Subject being in the exclusion period of another study or provided for by the "National Volunteer File". * Subjects with intracranial hypertension * Subject unlikely to cooperate with the study and / or weak cooperation anticipated by the investigator. * Treatment with buproprion or varenicline in progress * Episode or family history of epilepsy, convulsion. * Disease causing damage to the brain (aneurysm, tumor, ...). * Cochlear or ocular implant. * Stimulator or cardiac defibrillator. * Presence of metal in the skull (clip on aneurysm, prosthesis, ...). * Eczema on the scalp.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Adults (male and female subjects) with tobacco dependence are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Behavior, Addictive nicotine dependence substance dependence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Adults (male and female subjects) with tobacco dependence

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Psychiatrie Adultes Et Addictologie

    RECRUITING

    Paris, IDF, 75006, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.